Hims Enters TRT Market with FDA-Approved Oral KYZATREX — What the New Telehealth TRT Wave Means for Men

The testosterone replacement therapy market just got a major new player. Hims & Hers Health (NASDAQ: HIMS), one of the largest direct-to-consumer telehealth platforms in the United States, announced in early 2026 that it is entering the TRT space with an exclusive offering: FDA-approved oral testosterone, available through a partnership with Marius Pharmaceuticals.

The announcement, made via the company's newsroom, marks a significant expansion for Hims — and a signal of where the $4+ billion testosterone therapy market is heading. With major telehealth platforms increasingly competing for the millions of American men dealing with low testosterone, the competition is heating up. And that competition is good news for men who have historically struggled to access convenient, affordable TRT.

What Hims Is Offering

The Hims TRT platform will include several treatment pathways:

KYZATREX® — FDA-Approved Oral Testosterone

The centerpiece of the offering is KYZATREX, an FDA-approved oral testosterone formulation developed by Marius Pharmaceuticals. In clinical trials, KYZATREX restored testosterone levels in up to 96% of men with low testosterone, with an average doubling of free testosterone levels — the form of testosterone most associated with energy, mood, libido, and physical performance.

KYZATREX represents one of the few FDA-approved oral testosterone options on the market. Unlike injectable testosterone (which requires needles and regular clinic visits) or topical gels (which can transfer to partners or clothing), oral testosterone offers a needle-free, discreet option that fits into a daily routine.

Compounded Enclomiphene

In addition to KYZATREX, Hims will offer compounded enclomiphene — a selective estrogen receptor modulator (SERM) that stimulates the body's own testosterone production by activating pituitary signaling. Enclomiphene does not introduce external testosterone; instead, it encourages the body to produce more of its own.

This is significant because enclomiphene addresses one of the primary concerns men have about traditional TRT: fertility preservation. Men on conventional testosterone therapy often experience testicular shrinkage and reduced sperm production because external testosterone suppresses the body's natural production. Enclomiphene, by contrast, preserves fertility — a major selling point for younger men or those planning to have children.

Hims' compounded enclomiphene offering puts them in direct competition with companies like T·TIME, which launched in February 2026 with a similar enclomiphene-based TRT alternative.

Dual-Action Treatment: Enclomiphene + Tadalafil

Perhaps the most novel offering is a combination therapy: enclomiphene + tadalafil (the active ingredient in Cialis) in a single dual-action treatment. This combination targets both testosterone levels and sexual function simultaneously — addressing the two most common concerns for men with low testosterone: low energy/libido and erectile dysfunction.

At-Home Blood Testing

All Hims TRT patients will start with an at-home blood test, with results available in days rather than the weeks or months that traditional clinic-based testing often takes. This streamlined diagnostic pathway lowers the barrier to entry and makes TRT accessible to men who might otherwise avoid the hassle of in-person lab visits.

Injectable Testosterone Coming in 2026

Hims also announced plans to introduce an injectable testosterone option later in 2026, giving patients even more choice in how they receive treatment. The injectable offering will complement — not replace — the oral and enclomiphene options.

Why This Matters for the TRT Market

Hims & Hers is not the first telehealth company to enter TRT — but it is one of the largest. The company has built its brand on direct-to-consumer healthcare for hair loss, erectile dysfunction, skincare, and mental health. Their entry into TRT signals that the market is too large and too underserved to ignore.

Consider the numbers: an estimated 20 million men in the United States have low testosterone, yet the vast majority never receive treatment. Barriers include stigma, cost, lack of access to specialized clinics, and the inconvenience of traditional treatment pathways. Telehealth platforms like Hims address each of these barriers head-on.

The competitive landscape is quickly taking shape:

• MangoRx — launched in late 2025 with $99/month all-inclusive injectable TRT
• T·TIME — launched in February 2026 with oral enclomiphene-based TRT alternative
• Hims & Hers — entering 2026 with KYZATREX oral testosterone + enclomiphene + dual-action combo
• Traditional TRT clinics — still dominant but increasingly pressured by DTC telehealth alternatives

This competition is driving innovation in treatment options, pricing transparency, and patient experience. For men who have been on waiting lists at traditional TRT clinics or hesitant to seek treatment, the new telehealth options represent a meaningful shift in what's available.

What This Means for You

If you're one of the millions of men dealing with low testosterone symptoms — fatigue, low libido, mood changes, difficulty building muscle, brain fog — the options have never been better. Here's what to consider:

If you want traditional testosterone replacement: Injectable or oral testosterone (like KYZATREX) provides direct testosterone replacement. This is the most effective approach for men with severely low testosterone. The trade-off: some men experience testicular shrinkage and reduced fertility.

If fertility is a concern: Enclomiphene-based approaches (offered by both Hims and T·TIME) stimulate your body's own testosterone production, preserving fertility. This is ideal for younger men or those planning to have children.

If you want convenience: All of these telehealth platforms offer at-home testing, online consultations, and home delivery of medications — no more waiting rooms or frequent clinic visits.

If cost is a concern: Competition is driving prices down. MangoRx at $99/month set a new floor; Hims and others are competing on value as well as convenience. Check for insurance coverage, HSA/FSA eligibility, and manufacturer discount programs.

The most important thing is to get tested. Low testosterone is a medical condition with real symptoms and proven treatment options. The stigma that has held men back from seeking care is fading — helped along by telehealth platforms that make the process discrete, convenient, and affordable.

The Bigger Picture

Hims' entry into TRT is part of a broader shift in how men access healthcare. Just as telemedicine revolutionized birth control, hair loss treatment, and mental health care, it's now reshaping testosterone therapy. The combination of at-home testing, online prescribing, home delivery, and multiple treatment modalities (oral, injectable, enclomiphene) creates a patient experience that would have been unthinkable a decade ago.

The question for the market is whether this expansion will be matched by appropriate medical oversight — ensuring that men getting TRT through telehealth platforms receive proper monitoring for prostate health, hematocrit levels, cardiovascular risk, and other factors that matter for long-term TRT safety. Reputable telehealth providers incorporate this monitoring; men should ensure their chosen provider does as well.

What is clear is that the TRT market will look very different in 2027 than it did in 2025. Competition is up. Options are up. Accessibility is up. For men who need treatment, that's a positive trend.

What is KYZATREX?

KYZATREX is an FDA-approved oral testosterone formulation that restores testosterone levels in men with low testosterone. In clinical trials, it achieved normal testosterone levels in up to 96% of men, making it one of the most effective oral TRT options available. It was developed by Marius Pharmaceuticals and will be available exclusively through Hims & Hers as of 2026.

How is enclomiphene different from traditional TRT?

Traditional TRT (testosterone replacement therapy) introduces external testosterone into the body, which can suppress the body's natural testosterone and sperm production. Enclomiphene, by contrast, is a selective estrogen receptor modulator (SERM) that stimulates the pituitary gland to produce more luteinizing hormone (LH), which in turn tells the testes to produce more testosterone. The result: your body makes more testosterone on its own, preserving fertility and avoiding testicular shrinkage.

Can I get TRT through Hims without insurance?

Yes. Hims & Hers operates on a direct-to-consumer model, meaning you don't need insurance to access their TRT services. Pricing varies by treatment type, and the company has positioned itself as an affordable alternative to traditional TRT clinics. However, if you do have insurance, some plans may cover portions of the cost — check with your provider.

Is enclomiphene safe for long-term use?

Enclomiphene has been studied for extended use in men with low testosterone and is generally considered safe when prescribed and monitored by a qualified healthcare provider. The most common side effects include mild hot flashes, mood changes, and headaches. Because enclomiphene works through estrogen modulation, men with a history of estrogen-sensitive conditions should discuss risks with their provider.